|The following article features coverage from the Society of Gynecologic Oncology 2019 meeting. Click here to read more of Cancer Therapy Advisor‘s conference coverage.|
A retrospective multi-institutional study evaluated the clinical experiences of a small cohort of women with epithelial ovarian cancer who received a poly ADP ribose polymerase (PARP) inhibitor as part of 2 distinct lines of therapy and found that a partial response (PR) to the second PARP inhibitor occurred only in women who had a complete response (CR) to the first PARP inhibitor and also had a deleterious germline BRCA mutation. These findings were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.
Documented responses for the 21 identified patients following administration of the first PARP inhibitor (ie, velaparib [57.1%], olaparib [28.6%], and rucaparib [14.3%]) were 10 CR, 3 PR, 4 stable disease (SD), and 2 progressive disease (PD), and maintenance therapy was administered to 3 patients. Corresponding response data following administration of the second PARP inhibitor (ie, niraparib [42.9%], olaparib [28.6%], and rucaparib [28.6%]), were 3 PR, 13 SD, and 2 PD, and maintenance therapy was administered to 3 patients.
Discontinuation of PARP inhibitor therapy due to toxicity occurred in 9.5% and 28.6% of patients receiving the first and second PARP inhibitors, respectively. Grade 3/4 thrombocytopenia occurred in 25% of patients. In this small patient cohort, toxicity related to the first PARP inhibitor did not predict for toxicity related to the second PARP inhibitor.
“Now that there are three [U.S. Food and Drug Administration]-approved PARP inhibitors for different indications, repeat use of PARP inhibitors may become more common. More data are needed regarding the efficacy and safety of this approach,” the authors wrote in conclusion.
Read more of Cancer Therapy Advisor‘s coverage of the SGO 2019 meeting by visiting the conference page.
- Essel KG, Behbakht K, Lai T, et al. PARPi after PARPi in epithelial ovarian cancer. Data presented at: Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer; Honolulu, Hawaii; March 16-19, 2019. Abstract 7.